Spontaneous mutations in the single TTN gene represent high tumor mutation burden
暂无分享,去创建一个
Insuk Sohn | Se Jin Jang | I. Sohn | S. Jang | C. Sung | Jihun Kim | Chang Ohk Sung | Jihun Kim | Sung-Min Chun | Ji-Hye Oh | Eun Jeong Cho | Ji-Young Lee | Ji-Young Lee | S. Chun | Ji-Hye Oh | E. J. Cho
[1] Olaf Neumann,et al. Size matters: Dissecting key parameters for panel‐based tumor mutational burden analysis , 2018, International journal of cancer.
[2] Wyeth W Wasserman,et al. FLAGS, frequently mutated genes in public exomes , 2014, BMC Medical Genomics.
[3] Ahmet Zehir,et al. Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] Syed Haider,et al. Ensembl BioMarts: a hub for data retrieval across taxonomic space , 2011, Database J. Biol. Databases Curation.
[5] S. H. Wilson,et al. Mammalian base excision repair by DNA polymerases delta and epsilon. , 1998, Oncogene.
[6] M. Daly,et al. PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes , 2003, Nature Genetics.
[7] Y. Nakamura,et al. Genetic alterations during colorectal-tumor development. , 1988, The New England journal of medicine.
[8] J. Wolchok,et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. , 2014, The New England journal of medicine.
[9] Yassen Assenov,et al. Maftools: efficient and comprehensive analysis of somatic variants in cancer , 2018, Genome research.
[10] Jorge Sabbaga,et al. Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice , 2015, Oncotarget.
[11] Steven Henikoff,et al. SIFT: predicting amino acid changes that affect protein function , 2003, Nucleic Acids Res..
[12] Levi Garraway,et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden , 2017, Genome Medicine.
[13] P. Bork,et al. A method and server for predicting damaging missense mutations , 2010, Nature Methods.
[14] Hua Tan,et al. Genome-wide mutational spectra analysis reveals significant cancer-specific heterogeneity , 2015, Scientific Reports.
[15] Richard M. Simon,et al. Using cross-validation to evaluate predictive accuracy of survival risk classifiers based on high-dimensional data , 2011, Briefings Bioinform..
[16] Steven A. Roberts,et al. Mutational heterogeneity in cancer and the search for new cancer genes , 2014 .
[17] M. Perucho,et al. Microsatellite instability: The mutator that mutates the other mutator , 1996, Nature Medicine.
[18] Conrad A. Nieduszynski,et al. Genome-wide analysis of DNA replication timing in single cells: Yes! We’re all individuals , 2019, Genome Biology.
[19] Tae Won Kim,et al. Mutation Burden and I Index for Detection of Microsatellite Instability in Colorectal Cancer by Targeted Next-Generation Sequencing. , 2019, The Journal of molecular diagnostics : JMD.
[20] C. Dang,et al. Cancer genetics: Tumor suppressor meets oncogene , 1999, Current Biology.
[21] M. DePristo,et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.
[22] Richard Durbin,et al. Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .
[23] Isabelle Salmon,et al. Methods of measurement for tumor mutational burden in tumor tissue. , 2018, Translational lung cancer research.
[24] Laurent Farinelli,et al. Impact of replication timing on non-CpG and CpG substitution rates in mammalian genomes. , 2010, Genome research.
[25] C. Jefford,et al. Mechanisms of chromosome instability in cancers. , 2006, Critical reviews in oncology/hematology.
[26] Martin L. Miller,et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.
[27] S. H. Wilson,et al. Mammalian base excision repair by DNA polymerases δ and ε , 1998, Oncogene.
[28] K. Kinzler,et al. Lessons from Hereditary Colorectal Cancer , 1996, Cell.
[29] Li Ding,et al. Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. , 2018, Cell systems.
[30] K. Hess,et al. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. , 2011, JAMA.
[31] Steven J. M. Jones,et al. Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.
[32] Yi-Chen Yeh,et al. Mutation load estimation model as a predictor of the response to cancer immunotherapy , 2018, npj Genomic Medicine.
[33] S. Ramalingam,et al. Tumor Mutation Burden: Leading Immunotherapy to the Era of Precision Medicine? , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] F. Cunningham,et al. The Ensembl Variant Effect Predictor , 2016, Genome Biology.
[35] Richard Durbin,et al. Fast and accurate long-read alignment with Burrows–Wheeler transform , 2010, Bioinform..